Join the Dupilumab group to help and get support from people like you.
Dupilumab News
FDA Approves Dupilumab for Children With Eosinophilic Esophagitis
MONDAY, Jan. 29, 2024 – The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of pediatric patients (aged 1 to 11 years) with eosinophilic esophagitis (EoE). This...
Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...
Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the...
Many Primary Care Docs Unaware of Biologic Asthma Meds
TUESDAY, Nov. 21, 2023 – Biologic drugs to treat asthma have been around for two decades, but a surprising number of family doctors still aren’t prescribing them to kids and adults. A new survey f...
Lymphoid Reaction Observed in Eczema Patients Receiving Dupilumab
MONDAY, Oct. 30, 2023 – For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL),...
Dupilumab Treatment Beneficial for Sleep in Atopic Dermatitis
TUESDAY, Aug. 22, 2023 – For adults with moderate-to-severe atopic dermatitis (AD), dupilumab treatment yields significant improvement in sleep quality and other AD-related signs and symptoms,...
Dupilumab Reduces Exacerbations in Patients With COPD
THURSDAY, May 25, 2023 – For patients with chronic obstructive pulmonary disease (COPD) with type 2 inflammation, dupilumab is associated with fewer moderate-to-severe exacerbations, according to a...
Dupilumab Beneficial for Adults With Prurigo Nodularis
WEDNESDAY, May 10, 2023 – For adults with prurigo nodularis (PN), dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13,...
Dupixent (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis...
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood Children treated with Dupixent and topical corticosteroids (TCS)...
FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent...
FDA Expands Approval of Dupixent (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
TARRYTOWN, N.Y. and PARIS, Oct. 20, 2021 /PRNewswire/ – Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting...
FDA Approves New Dupixent (dupilumab) Pre-Filled Pen Designed to Support More Convenient Self-Administration
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 19, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a 300 mg single-dose pre-filled pen for Dupixent® (dupilumab). The pre-fi...
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
TARRYTOWN, N.Y. and PARIS, May 26, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupi...
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Contact Dermatitis, Atopic Dermatitis, Eczema, Asthma - Maintenance, Asthma, Allergies